From urine to blood: How antibiotic resistance spreads

Image
ANI Washington D.C. [USA]
Last Updated : Apr 23 2017 | 11:13 AM IST

People with drug-resistant bacteria in their urine or stool samples are at an increased risk of developing Sepsis, a bloodstream infection that is also resistant to certain antibiotics, according to a recent study.

Sepsis affects an estimated 30 million people worldwide each year. Without quick treatment, it can lead to multiple organ failure and death. Treating sepsis can be even more difficult if the bacteria responsible are resistant to antibiotics.

Presenting the research at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Joakim Isendahl from the Karolinska Institutet, Sweden told the congress that in some cases bacteria may be spreading from the bowel or urinary tract into the bloodstream, while in others the bacteria found in patients' urine or stool samples could be transferring their ability to resist antibiotics to other bacteria in the body, which then can cause sepsis.

The study of 66,000 people showed that the risk of drug-resistant sepsis is highest soon after drug-resistant bacteria have been detected in a patient's urine or stool, and that this risk diminishes over time. The researchers say their finding could help doctors diagnose drug-resistant sepsis and inform treatment choices.

The research focused on certain bacteria, such as Escherichia coli, that produce enzymes called extended spectrum Beta-lactamases. These enzymes allow bacteria to break down a variety of antibiotics including penicillin and third-generation cephalosporins. These drug-resistant bacteria are known as extended-spectrum Beta-lactamase-producing Enterobacteriaceae, or EPE.

Researchers studied all subjects who were found to have these types of bacteria in their urine or stool samples in Sweden between 2007 and 2012, more than 22,000 in total. They compared them with an equivalent group of 44,000 people who had no diagnosis of EPE. They followed the subjects for six years to find out if they subsequently developed a bloodstream infection.

The data revealed that people whose bowels had been colonised previously by EPE were 57 times more likely to develop an EPE infection of the bloodstream, compared to the general population. For those with a previous finding of EPE in their urine, the risk was 113 times higher than the general population. Over the six-year study period, 2 percent of those with EPE in the bowel and 4 percent of those with a urinary tract infection went on to have a bloodstream infection with EPE. This compares to 0.02 percent in the general population.

Sepsis is treated with antibiotic drugs injected directly into the blood. One important drug group for sepsis treatment is called carbapenems. Carbapenems are often referred to as 'last-resort' drugs because they are some of the few that are effective against the increasing number of drug-resistant bacteria. Although these are life-saving treatments, experts have warned that over-use will lead to bacteria also developing resistance to carbapenems.

He explained: "Although bloodstream infections are rare, their consequences are dire and treatment must be given as quickly as possible.

"Knowing if a patient has had a previous finding of EPE, and how long ago it was, helps inform doctors on when last-resort drugs are essential, but also on when they are not needed. This is important since prudent use is imperative to keep them effective. We found that the riskiest time was in the days and weeks after the bacteria were found in the urine or stool sample, but there is still an increased risk up to three years later.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 23 2017 | 11:13 AM IST

Next Story